About Us
Our mission
At HBC Immunology, our mission is clear: to overcome treatment resistance in disease through AI-optimized peptide therapeutics. By targeting root causes of resistance, we aim to restore treatment efficacy, reactivate immune responses, and give patients better outcomes and renewed hope.
Our Values
We envision a world where no disease treatment is limited by resistance mechanisms.
Through the convergence of artificial intelligence, precision science, and patient-focused innovation, we're redefining patient care and turning intransigent diseases into manageable conditions.
- Innovation: Pushing the boundaries of treatment-resistance research with a unique combination of experience, innovation and experimentation.
- Collaboration: Partnering with researchers, clinicians, and industry leaders to drive progress.
- Patient-Centric Approach: Every decision is made with patients' needs and well-being at the core.
- Integrity: Maintaining transparency, trust, and scientific excellence in everything we do.
Our Leadership Team
Dr. Bomi Framroze PhD.
CEO & Founder
Dr. Bomi Framroze is an accomplished discovery research scientist with 33 years of experience and is credited with over 80 global patents and
publications. He has held senior corporate leadership roles as well as co-founded Gharda USA, ROW2 Technologies, Supportive Therapeutics & Hofseth Biocare AS. His research has contributed to advancing therapeutic strategies in systemic health, immunology and oncology.
Dr. Crawford Currie M.D.
Head of Medical Research
Dr. Crawford Currie is a Fellow of the Royal College of Surgeons who moved into oncology R&D at AstraZeneca after leaving clinical practice and then worked as a financial analyst and investor focused on healthcare companies. He has worked at Hofseth Biocare for the last 5
years supporting clinical trial strategy and commercialization.
James Berger
Head of Partnerships and Strategic Alliances
James started his career in Equities at Goldman Sachs International in 2001 and then joined JP Morgan as a VP from 2005. He then moved to the buyside and enjoyed a successful career as a Portfolio Manager for GLG Partners in London and then for Millennium Capital Management in Switzerland. Since June 2019 is the CCO for HBC and CIO for the wider Hofseth International group principally focused on finance, capital raising and strategic alliances.
Medical & Scientific Advisory Board
Prof. Dr. Stephen T. Sonis, DMD, DMSc
Advisory Board Member
Dr. Stephen T. Sonis is a senior academic at Harvard University, Brigham and Women’s Hospital and the Dana-Farber Cancer Institute and is a world-renowned expert on tissue toxicities of cancer therapy. His development of highly
translational models has enabled the investigation of cancer regimen-related tissue toxicities and
catalyzed development of potential therapies and innovative omics-based analytical approaches to
clinically actionable outcomes to personalize therapy. Dr. Sonis is internationally recognized as an expert clinical trialist. He has ongoing collaborations with academic centers to assess the fiscal burden of cancer and its sequelae.
Dr. Sonis holds several patents and is the author of more than 300 original publications, reviews, and
chapters and 11 books. His work has been cited more than 35,000 times. He received his DMD from Tufts, completed his DMSc and residency at Harvard, and his postdoctoral training in tumor immunology at Oxford where he was a Knox Fellow.
Prof. Dr. Karl G. Sylvester
Advisory Board Member
Dr. Karl G. Sylvester is a Professor of Surgery and Pediatrics at Stanford University School of Medicine where his clinical expertise is specialization in pediatric, neonatal, and fetal surgery. Dr. Sylvester also serves as Associate Dean of Maternal Child Health Research, where he is responsible for the governance, regulatory framework and implementation of best practices for clinical and translatioal research for Stanford Childrens’ Health. Dr. Sylvester is the Co-Director of the Stanford Metabolic Health Center, his research focuses on the discovery of novel molecular markers and insights of human disease. Dr. Sylvester’ investigations seek to develop innovative diagnostics and therapies utilizing a variety of technologies combining high content omic analyses with wearable technologies. The translational application of these studies is to address diseases of pregnancy and the newborn. Dr. Sylvester has extensive clinical trial experience across a variety of clinical patient settings. Dr. Sylvester is dedicated to advancing pediatric care through clinical excellence, research, and interdisciplinary collaboration.